Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 465-471, November 2006

Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: Early results

  • Kimberly A. Roehl, M.P.H.

      Affiliations

    • Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63105, USA
  • ,
  • Scott E. Eggener, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
  • ,
  • Stacy Loeb, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
  • ,
  • Norm D. Smith, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
  • ,
  • Jo Ann V. Antenor, M.P.H.

      Affiliations

    • Department of Neurology, Washington University School of Medicine, St. Louis, MO 63105, USA
  • ,
  • William J. Catalona, M.D.

      Affiliations

    • Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-312-695-4471; fax: +1-312-695-1482.

Received 17 August 2005; received in revised form 29 November 2005; accepted 30 November 2005.

Abstract 

Objective

Screening using a standardized protocol may improve outcomes of patients undergoing treatment for prostate cancer. We compared the 7- year progression-free survival rates after radical retropubic prostatectomy in patients whose prostate cancer was detected through a formal screening program with those of patients referred for treatment by other physicians who did not use a standardized screening/referral protocol.

Methods

A single surgeon (W.J.C.) performed radical retropubic prostatectomy in 3,177 consecutive patients between 1989 and 2003. Of these patients, 464 had cancer detected in a screening study, and 2,713 were referred from outside institutions. We compared the screened and referred cohorts for age at surgery, clinical stage, pathologic stage, Gleason sum, preoperative prostate-specific antigen (PSA) levels, and adjuvant radiation therapy. Kaplan-Meier product limit estimates were used to calculate 7-year progression-free probabilities, and Cox proportional hazards models were used to determine the clinical and pathologic parameters associated with cancer progression in each group.

Results

The overall 7-year progression-free survival rates were 83% for the screened patients compared with 77% for the referred patients (P = 0.002). Preoperative PSA, Gleason sum, clinical stage, pathologic stage, and adjuvant radiotherapy were all significantly associated with cancer progression. There was a significantly higher proportion of referred patients with a preoperative PSA ≥10, Gleason sum ≥7, and nonorgan-confined disease.

Conclusions

Patients with screened-detected prostate cancer have more favorable clinical and pathologic features, and 7-year progression-free survival rates than referred patients. On multivariate analysis, including other clinical variables, screening status was a significant independent predictor of biochemical outcome.

Keywords: Prostate, Prostatic neoplasms, Prostate-specific antigen, Screening, Radical prostatectomy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a grant from Beckman Coulter Incorporated, Fullerton, CA, and by the Urological Research Foundation.

PII: S1078-1439(05)00305-4

doi:10.1016/j.urolonc.2005.11.039

Urologic Oncology: Seminars and Original Investigations
Volume 24, Issue 6 , Pages 465-471, November 2006